SNYNF — Sanofi
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1121404 ·
Last close
$87.45
Market Cap
$104.67B
52W High
$96.41
52W Low
$80.74
ADV30
5,260
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 11,244,000,000 | 8,106,000,000 | 2,269,000,000 | 1,614,000,000 | 128,024,000,000 | 5,544,000,000 | 54,881,000,000 |
| Dec 2025 | 12,205,000,000 | 8,449,000,000 | 1,630,000,000 | -801,000,000 | 126,805,000,000 | 7,657,000,000 | 55,095,000,000 |
| Sep 2025 | 13,170,000,000 | 9,758,000,000 | 3,785,000,000 | 2,802,000,000 | 129,794,000,000 | 8,906,000,000 | 56,261,000,000 |
| Jun 2025 | 10,735,000,000 | 7,743,000,000 | 1,712,000,000 | 3,940,000,000 | 124,959,000,000 | 15,359,000,000 | 54,680,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$10,336,000,000
Investing CF
$-14,175,000,000
Financing CF
$-9,102,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.74
As of
2026-05-10
Yahoo Snapshot (yfinance, live)
Total Revenue
$47,353,999,360
EBITDA
$12,826,999,808
Free Cash Flow
$16,672,499,712
Enterprise Value
$121,203,073,024
Total Cash
$5,544,000,000
Total Debt
$20,021,000,192
Shares Out
1,196,884,513
Trailing EPS
$4.51
Book Value
$69.36
ROE
6.6%
ROA
4.7%
Div Yield
5.53%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,716,000,000 | 9,597,000,000 | 7,813,000,000 | 126,805,000,000 | 55,095,000,000 | — | 10,750,000,000 |
| Dec 2024 | 44,286,000,000 | 8,923,000,000 | 5,560,000,000 | 132,798,000,000 | 54,941,000,000 | — | 9,081,000,000 |
| Dec 2023 | 41,618,000,000 | 8,691,000,000 | 5,400,000,000 | 126,464,000,000 | 52,111,000,000 | — | 10,258,000,000 |
| Dec 2022 | 40,561,000,000 | 10,926,000,000 | 8,371,000,000 | 126,722,000,000 | 51,570,000,000 | — | 10,526,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNY | Sanofi | $104.13B | $43.50 | — |
| GLAXF | GSK plc | $105.31B | $26.29 | — |
| GSK | GSK plc | $105.71B | $52.78 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $117.58B | $57.58 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $123.19B | $485.39 | — |
News headlines (Yahoo Finance, 1h cache)
Sanofi (ENXTPA:SAN) Could Be 21% Undervalued As FDA Clears Sarclisa Escena
2026-07-11 06:14 · Yahoo
Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe
2026-07-11 05:13 · Yahoo
Sanofi: Information concerning the total number of voting rights and shares - June 2026
2026-07-10 16:30 · Yahoo
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
2026-07-10 12:35 · Yahoo
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
2026-07-07 11:00 · Yahoo
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
2026-07-06 15:55 · Yahoo
R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy
2026-07-05 22:52 · Yahoo
ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI
2026-07-03 16:00 · Yahoo
Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth
2026-07-03 08:40 · Yahoo
[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growt
2026-07-03 08:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.